Skip to main content
. 2022 Jan 25;12:786706. doi: 10.3389/fphar.2021.786706

FIGURE 4.

FIGURE 4

Mean changes in risk markers from baseline to 6-months in the subset of the EMPA-REG OUTCOME trial according to the EMPA-KIDNEY trial inclusion criteria (N = 1222). Changes are presented as mean with 95% confidence intervals, for the placebo and empagliflozin group. HbA1c, glycated hemoglobin; UACR, urinary-albumin-creatinine-ratio; BP, blood pressure; HDL, high-density-lipoprotein; LDL, low-density-lipoprotein.